218 related articles for article (PubMed ID: 15634232)
21. 1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis.
Durand KS; Guillaudeau A; Weinbreck N; DeArmas R; Robert S; Chaunavel A; Pommepuy I; Bourthoumieu S; Caire F; Sturtz FG; Labrousse FJ
Mod Pathol; 2010 Apr; 23(4):619-28. PubMed ID: 20081802
[TBL] [Abstract][Full Text] [Related]
22. [Histological classification of human gliomas: state of art and controversies].
Figarella-Branger D; Bouvier C
Bull Cancer; 2005 Apr; 92(4):301-9. PubMed ID: 15888386
[TBL] [Abstract][Full Text] [Related]
23. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
Born PW; Broholm H; Laursen H
Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
[TBL] [Abstract][Full Text] [Related]
24. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical characterization of spontaneous and acrylonitrile-induced brain tumors in the rat.
Kolenda-Roberts HM; Harris N; Singletary E; Hardisty JF
Toxicol Pathol; 2013 Jan; 41(1):98-108. PubMed ID: 22821367
[TBL] [Abstract][Full Text] [Related]
26. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
[TBL] [Abstract][Full Text] [Related]
27. Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA.
Tabu K; Ohba Y; Suzuki T; Makino Y; Kimura T; Ohnishi A; Sakai M; Watanabe T; Tanaka S; Sawa H
Mol Cancer Res; 2007 Oct; 5(10):1099-109. PubMed ID: 17951409
[TBL] [Abstract][Full Text] [Related]
28. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.
Kim SH; Kim H; Kim TS
Acta Neuropathol; 2005 Jul; 110(1):27-38. PubMed ID: 15920661
[TBL] [Abstract][Full Text] [Related]
29. A novel function of OLIG2 to suppress human glial tumor cell growth via p27Kip1 transactivation.
Tabu K; Ohnishi A; Sunden Y; Suzuki T; Tsuda M; Tanaka S; Sakai T; Nagashima K; Sawa H
J Cell Sci; 2006 Apr; 119(Pt 7):1433-41. PubMed ID: 16554441
[TBL] [Abstract][Full Text] [Related]
30. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
Gupta M; Djalilvand A; Brat DJ
Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285
[TBL] [Abstract][Full Text] [Related]
31. [Expression of myelin basic protein and glial fibrillary acidic protein genes in human glial brain tumors].
Dmytrenko VV; Boĭko OI; Shostak KO; Bilets'kyĭ AV; Malysheva TA; Shamaiev MI; Kliuchka VM; Rozumenko VD; Zozulia IuP; Kavsan VM
Tsitol Genet; 2009; 43(1):28-35. PubMed ID: 19663312
[TBL] [Abstract][Full Text] [Related]
32. Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas.
Yokoo H; Nobusawa S; Takebayashi H; Ikenaka K; Isoda K; Kamiya M; Sasaki A; Hirato J; Nakazato Y
Am J Pathol; 2004 May; 164(5):1717-25. PubMed ID: 15111318
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of malignant features in oligodendroglial tumors.
Saito A; Nakazato Y
Clin Neuropathol; 1999; 18(2):61-73. PubMed ID: 10192700
[TBL] [Abstract][Full Text] [Related]
34. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology.
Ikota H; Kinjo S; Yokoo H; Nakazato Y
Acta Neuropathol; 2006 May; 111(5):475-82. PubMed ID: 16598485
[TBL] [Abstract][Full Text] [Related]
35. Genetic fate mapping of Olig2 progenitors in the injured adult cerebral cortex reveals preferential differentiation into astrocytes.
Tatsumi K; Takebayashi H; Manabe T; Tanaka KF; Makinodan M; Yamauchi T; Makinodan E; Matsuyoshi H; Okuda H; Ikenaka K; Wanaka A
J Neurosci Res; 2008 Dec; 86(16):3494-502. PubMed ID: 18816798
[TBL] [Abstract][Full Text] [Related]
36. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical comparative analysis of GFAP, MAP - 2, NOGO - A, OLIG - 2 and WT - 1 expression in WHO 2016 classified neuroepithelial tumours and their prognostic value.
Schwab DE; Lepski G; Borchers C; Trautmann K; Paulsen F; Schittenhelm J
Pathol Res Pract; 2018 Jan; 214(1):15-24. PubMed ID: 29258767
[TBL] [Abstract][Full Text] [Related]
38. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.
Jenkinson MD; Smith TS; Joyce KA; Fildes D; Broome J; du Plessis DG; Haylock B; Husband DJ; Warnke PC; Walker C
Neuroradiology; 2006 Oct; 48(10):703-13. PubMed ID: 16937145
[TBL] [Abstract][Full Text] [Related]
39. Ezrin expression in tissue microarray of primary and recurrent gliomas.
Tynninen O; Carpén O; Jääskeläinen J; Paavonen T; Paetau A
Neuropathol Appl Neurobiol; 2004 Oct; 30(5):472-7. PubMed ID: 15488023
[TBL] [Abstract][Full Text] [Related]
40. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas.
Senetta R; Trevisan E; Rudà R; Maldi E; Molinaro L; Lefranc F; Chiusa L; Lanotte M; Soffietti R; Cassoni P
J Neuropathol Exp Neurol; 2009 Apr; 68(4):425-31. PubMed ID: 19287309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
